- Home
- TNXP vs ESPR Comparison
TNXP vs ESPR Comparison
Compare TNXP & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- ESPR
- Stock Information
- Founded
- TNXP 2007
- ESPR 2008
- Country
- TNXP United States
- ESPR United States
- Employees
- TNXP N/A
- ESPR N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- TNXP Health Care
- ESPR Health Care
- Exchange
- TNXP Nasdaq
- ESPR Nasdaq
- Market Cap
- TNXP 207.5M
- ESPR 208.1M
- IPO Year
- TNXP N/A
- ESPR 2013
- Fundamental
- Price
- TNXP $33.33
- ESPR $1.07
- Analyst Decision
- TNXP Strong Buy
- ESPR Buy
- Analyst Count
- TNXP 2
- ESPR 7
- Target Price
- TNXP $585.00
- ESPR $5.93
- AVG Volume (30 Days)
- TNXP 1.1M
- ESPR 4.1M
- Earning Date
- TNXP 08-15-2025
- ESPR 08-11-2025
- Dividend Yield
- TNXP N/A
- ESPR N/A
- EPS Growth
- TNXP N/A
- ESPR N/A
- EPS
- TNXP N/A
- ESPR N/A
- Revenue
- TNXP $10,041,000.00
- ESPR $259,574,000.00
- Revenue This Year
- TNXP $11.66
- ESPR $4.07
- Revenue Next Year
- TNXP $793.18
- ESPR N/A
- P/E Ratio
- TNXP N/A
- ESPR N/A
- Revenue Growth
- TNXP N/A
- ESPR 12.99
- 52 Week Low
- TNXP $6.76
- ESPR $0.69
- 52 Week High
- TNXP $137.25
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- TNXP 52.50
- ESPR 51.40
- Support Level
- TNXP $33.41
- ESPR $1.13
- Resistance Level
- TNXP $37.42
- ESPR $1.22
- Average True Range (ATR)
- TNXP 3.48
- ESPR 0.08
- MACD
- TNXP -1.12
- ESPR 0.00
- Stochastic Oscillator
- TNXP 33.66
- ESPR 52.38
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.